Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to -$31.1 million.

  • Tango Therapeutics' Free Cash Flow rose 716.91% to -$31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$146.8 million, marking a year-over-year decrease of 1914.97%. This contributed to the annual value of -$132.3 million for FY2024, which is 1066.62% down from last year.
  • Per Tango Therapeutics' latest filing, its Free Cash Flow stood at -$31.1 million for Q3 2025, which was up 716.91% from -$37.1 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Free Cash Flow peaked at -$8.0 million during Q2 2021, and registered a low of -$41.7 million during Q1 2025.
  • Moreover, its 5-year median value for Free Cash Flow was -$31.1 million (2025), whereas its average is -$28.4 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 2501865000.0% in 2021, then skyrocketed by 2462.44% in 2023.
  • Quarter analysis of 5 years shows Tango Therapeutics' Free Cash Flow stood at -$17.6 million in 2021, then crashed by 66.54% to -$29.3 million in 2022, then grew by 5.51% to -$27.7 million in 2023, then plummeted by 32.78% to -$36.8 million in 2024, then increased by 15.41% to -$31.1 million in 2025.
  • Its Free Cash Flow stands at -$31.1 million for Q3 2025, versus -$37.1 million for Q2 2025 and -$41.7 million for Q1 2025.